Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Explore this paper's citation graph
Summary
Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
- Type
- article
- Published
- 1998-11-05
- Cited by
- 5,491
- References
- 17
- Access
- Open access
- OpenAlex
- https://openalex.org/W38523360
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24236195
Keywords
Pravastatin, Medicine, Myocardial infarction, Internal medicine, Relative risk
References
- Apparent discontinuation rates in patients prescribed lipid‐lowering drugs
- Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.
- Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
- Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study
- 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service.
- Unstable angina: pathogenesis, diagnosis, and treatment.
- Range of serum cholesterol values in the population developing coronary artery disease.
- Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group.
- A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
- Statistical Methods for Survival Data Analysis
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
- The value of lowering cholesterol after myocardial infarction.
- A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results.
- CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT
- Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
Cited by
- Tratamiento médico de la angina estable: Fármacos antianginosos y prevención secundaria de la cardiopatía isquémica
- The effects of pharmaceutical care provision on patients with acute coronary syndromes and
- New insights into immunological aspects of atherosclerosis.
- Joint British recommendations on prevention of coronary heart disease in clinical practice
- Non‐lipid properties of statins
- Secondary prevention in coronary heart disease
- Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
- Cholesterol lowering and endothelial function.
- Beyond lipids - the role of the endothelium in coronary artery disease.
- Is cholesterol a risk factor for stroke?: No.
- Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.
- Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease
- Current concepts in secondary prevention after acute myocardial infarction
- Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial.
- Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.
- Lipid-lowering drug therapies: the evidence
- Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
- Interim monitoring of clinical trials based on long-term binary endpoints.
- How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
- Clinical implications of clinical studies: can we compare different subgroups defined a posteriori?
Related papers
- Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
- The heart in fatal unstable angina pectoris.
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
- Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)
- The definitions of acute coronary syndrome, myocardial infarction, and unstable angina
- Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes.
- Lipoprotein (a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it is not predictive of the severity of coronary lesions
- Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
- Pravastatin and coronary heart disease.